4′-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN

Suh Young Jeong, Penelope Hogarth, Andrew Placzek, Allison M. Gregory, Rachel Fox, Dolly Zhen, Jeffrey Hamada, Marianne van der Zwaag, Roald Lambrechts, Haihong Jin, Aaron Nilsen, Jared Cobb, Thao Pham, Nora Gray, Martina Ralle, Megan Duffy, Leila Schwanemann, Puneet Rai, Alison Freed, Katrina WakemanRandall L. Woltjer, Ody C.M. Sibon, Susan J. Hayflick

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Pantothenate kinase-associated neurodegeneration (PKAN) is an inborn error of CoA metabolism causing dystonia, parkinsonism, and brain iron accumulation. Lack of a good mammalian model has impeded studies of pathogenesis and development of rational therapeutics. We took a new approach to investigating an existing mouse mutant of Pank2 and found that isolating the disease-vulnerable brain revealed regional perturbations in CoA metabolism, iron homeostasis, and dopamine metabolism and functional defects in complex I and pyruvate dehydrogenase. Feeding mice a CoA pathway intermediate, 4′-phosphopantetheine, normalized levels of the CoA-, iron-, and dopamine-related biomarkers as well as activities of mitochondrial enzymes. Human cell changes also were recovered by 4′-phosphopantetheine. We can mechanistically link a defect in CoA metabolism to these secondary effects via the activation of mitochondrial acyl carrier protein, which is essential to oxidative phosphorylation, iron–sulfur cluster biogenesis, and mitochondrial fatty acid synthesis. We demonstrate the fidelity of our model in recapitulating features of the human disease. Moreover, we identify pharmacodynamic biomarkers, provide insights into disease pathogenesis, and offer evidence for 4′-phosphopantetheine as a candidate therapeutic for PKAN.

Original languageEnglish (US)
Article numbere10489
JournalEMBO Molecular Medicine
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2019

Keywords

  • 4′-phosphopantetheine
  • NBIA
  • PANK2
  • PKAN
  • coenzyme A

ASJC Scopus subject areas

  • Molecular Medicine

Fingerprint Dive into the research topics of '4′-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN'. Together they form a unique fingerprint.

  • Cite this

    Jeong, S. Y., Hogarth, P., Placzek, A., Gregory, A. M., Fox, R., Zhen, D., Hamada, J., van der Zwaag, M., Lambrechts, R., Jin, H., Nilsen, A., Cobb, J., Pham, T., Gray, N., Ralle, M., Duffy, M., Schwanemann, L., Rai, P., Freed, A., ... Hayflick, S. J. (2019). 4′-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN. EMBO Molecular Medicine, 11(12), [e10489]. https://doi.org/10.15252/emmm.201910489